

2023 20th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

<https://marketpublishers.com/r/18B83BBCB7FEN.html>

Date: April 2023

Pages: 3850

Price: US\$ 3,850.00 (Single User License)

ID: 18B83BBCB7FEN

Abstracts

The 2023 20th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biomanufacturers and contract manufacturing organizations' current and projected future capacity and production. In this year's annual report, we provide case study summaries highlighting a specific issue affecting the industry, an overview of the situation, and a discussion summary.

Highlights

This report's ~500 pages of data-rich analysis will help improve your decision-making in biomanufacturing operations, with an in-depth analysis of capacity, production trends, benchmarks, and much more.

Coverage

In-depth analysis of key data, capacity, production trends, and benchmarks

Budget trends and impact of the current economic environment

Downstream purification problems and issues

Current and projected industry bottlenecks

Capacity utilization and current production levels

Capacity bottlenecks – what's being done to resolve

Production trends and Outsourcing trends

International offshoring through 2028

Range of titers, growth

Disposables: Spending growth; downstream uses; L&E's; reasons for increasing/ restricting; budget increases; vendor satisfaction

Batch failure rates & trends

Selecting a CMO — Problems & solutions

Quality management & PAT implementation

Hiring and employment growth

Supplier growth rates, and much more

Contents

CHAPTER 0: DEMOGRAPHICS

Introduction

0-1 Respondents' Area of Involvement

0-2 Respondents' Qualifications

0-3 Facility Locations

0-4 Areas of Biopharmaceutical Manufacturing Operations

0-5 Production Operations, Phase of Development

0-6 Employees at Facility

0-7 Batches Run at Facility per Year

0-8 Single-Use Bioreactor Capacity in Use at Site

0-9 Stainless Steel Bioreactor Capacity in Use at Site

CHAPTER 1: INTRODUCTION AND DISCUSSION

1-1 Sector/Market Overview

“Biopharmaceutical”: The Definition Used Here

The Biopharma(ceutical) Industry is Losing its Core Identity

The Industry Continues to Mature

M&A Activities

Pharmaceutical Industry Dependence on Biopharmaceuticals

Supply Chain Planning in Biopharma

1-2 Biopharmaceutical Industry Status and Market Trends

US Healthcare is Changing

Bioprocessing is Increasing Internationally

1-3 Pharma Industry is Shifting to Biopharmaceuticals

1-4 Global Biopharmaceutical Market Trends

Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

Growth in Biopharmaceutical Product Sales is Increasing the Demand for Bioprocessing

Overall Health of the Biopharmaceutical Sector

U.S. Industry Leadership Continues

Biopharmaceuticals in the Rest-of-the-World

1-5 Biopharmaceutical Markets by Product Class

Monoclonal Antibodies (mAbs) are the Leading Product Class

1-6 Animal Derived Products and Biopharmaceuticals

The Rise of Plant-based Biopharmaceutical Manufacturing

1-7 Future Trends in the Biopharmaceutical Industry

CHAPTER 2: FUTURE OF BIOPROCESSING: EXPERTS' PERSPECTIVE

- 2-1 2022 FDA Biopharmaceutical Approvals: Therapy Options Diversify as Innovative Technologies Continue to Develop
- 2-2 Recent Transactions Affecting the CDMO Landscape
- 2-3 End-Of-Life Management for Single-Use Products in Bioproduction: Users Perspective on End-of-Life Management for Single-Use Products used in Bioproduction
- 2-4 China's Position in Global BioManufacturing: A Comparison of China's Emerging Position vs Established Regions' Manufacturing Capacity and Production
- 2-5 Impact of COVID-19 on Bioprocessing Supply Chain, Hiring, and Inventory
- 2-6 AI: The Future of Biopharmaceuticals - Impacting Drug Discovery and Development in 2023

CHAPTER 3: EMERGING TECHNOLOGIES

- 3-1 Industry Trends in 2023
 - Introduction
- 3-2 Bioprocessing Innovations Needed in 2023
 - Bioprocessing Innovations Most Needed
 - Novel Bioprocessing Systems/Innovations
 - Novel Bioprocessing Systems/Innovations, Biomanufacturers vs. CMOs
- 3-3 Operational Changes in 2023
 - Operational Changes (2010-2012, 2022-2023)
 - Operational Changes: U.S. vs. Western Europe
- 3-4 Budget Issues in 2023
 - Budget Change Comparisons
 - Top Bioprocessing Budget Expenditures
 - Top Bioprocessing Budget Expenditures (2020-2023)
- 3-5 New Bioprocessing Products Development Opportunities in 2023
 - Trends: Upstream New Product Areas of Need (2010-2023)
 - Downstream New Product Areas of Need
 - Trends: Downstream New Product Areas of Interest (2010-2023)
 - Other General New Product Areas of Need
 - Trends: Other General New Product Areas of Need (2010-2023)
- 3-6 Innovations in Single use/Disposable Equipment
 - Other Areas for Innovation
 - New Product Development Areas: Biomanufacturers vs. CMOs
 - New Product Development Areas: U.S. vs. Western Europe and ROW

3-7 Cost-Cutting Actions & Development Timelines
Cost-Cutting Changes: Specific to Outsourcing
Factors Impacting Reduction in Cost of Goods
3-8 Average Cost per Gram Recombinant Protein
Distribution, Average Cost per Gram for PRIMARY Recombinant Protein (2017-2023)
3-9 Assay Development
Assay Development (2019 data)
Biomanufacturing Assay Required; Biomanufacturers vs. CMOs (2019 data)
3-10 Selecting and Purchasing Commercial-Scale Bioreactors
Top Options for Bioreactor Platforms at Commercial Scale
Largest Stainless Steel Bioreactor Capacity Purchase in Next Two Years (2022 data)
Largest Single-Use Bioreactor Capacity Purchase in Next Two Years (2022 data)
3-11 Discussion: Industry Trends and Issues
Industry Growth and Adaptation
Cost Cutting Trends
Trends in Speeding Development and Approval Timelines
Discussion of Needed Single-use Innovations
Trends in Bioprocessing Industry Desires for Improved Products and Services

CHAPTER 4: CAPACITY UTILIZATION

4-1 Capacity Utilization Trends
Capacity Utilization Definitions
Relevance of Capacity Utilization
Capacity Utilization in Biomanufacturing, 2023
Capacity Utilization in Biomanufacturing, By System, 2023
Capacity Utilization Changes (2006-2023)
Average Growth Rate in Capacity Utilization (2006-2023)
4-2 Capacity Utilization: Biomanufacturers vs. CMOs
4-3 Capacity Utilization: U.S. vs. Western European Biomanufacturers
4-4 Respondents' Current Total Production Capacity
Mammalian Cell Culture
Estimated Bioreactor Capacity Distribution, Biotherapeutic Developers and CMOs
Largest Capacity Facilities
Biopharmaceutical Capacity Expansions Continue
Biopharmaceutical Developers/Manufacturers as CMOs
Major CMOs in Terms of Facilities and Capacity
Microbial Fermentation Capacity
Cell Therapy Capacity

Gene Therapy Capacity
4-5 Range of Titers with mAb Production
Annual mAb Titer Changes (2008-2023)
4-6 Discussion: Capacity and Industry Trends
Capacity Utilization
Over Capacity Trends

CHAPTER 5: CURRENT AND FUTURE CAPACITY CONSTRAINTS AND

QUALITY FACTORS

5-1 Current Capacity Constraints
Respondents Experiencing No Capacity Constraints
Respondents' Perception of Capacity Constraints (2004-2023)
Perception of Capacity Constraints: Biomanufacturers vs. CMOs
Capacity Constraints: U.S. vs. Western European Biomanufacturers & CMOs
5-2 Expected Capacity Constraints
Respondents' Expectations of Capacity Constraints by 2028
Expected Capacity Constraints by 2028 (2004-2023)
Expected Capacity Constraints by 2028: Biomanufacturers vs. CMOs
Expected Capacity Constraints by 2028: U.S. vs. Western Europe
5-3 Factors Impacting Future Production Capacity
Factors Creating Future Capacity Constraints
Factors Creating Future Capacity Constraints (2008-2023)
Factors Creating Future Capacity Constraints: Biomanufacturers vs. CMOs
CMO Capacity Bottleneck Projections, in Retrospect
Biotherapeutic Developers' Capacity Bottleneck Projections, in Retrospect
Factors Creating Capacity Constraints: U.S. vs. Western European Respondents
5-4 Key Areas to Address to Avoid Future Capacity Constraints
Analysis of Areas to Avoid Capacity Constraints: Changing Perspectives (2006-2023)
Key areas to Address to Avoid Capacity Constraints;
Biomanufacturers vs. CMOs
Key Areas to Address to Avoid Capacity Constraints: U.S. vs. Western Europe
5-5 Batch Failures in Biopharmaceutical Manufacturing
Average Time Between Batch Failures (2009-2023)
Batch Failure Frequency Distribution (2009-2023)
Primary Cause of Batch Failures, Percentages of Failures
5-6 Automation Implementation
Demand for Automation
Automation Implementation

Comparison of Implementation Plans (2009-2013, 2022-2023)
5-7 Quality Problems in Biomanufacturing Attributed to Vendors
Global Quality Supply Management
Global Quality Supply Management (2011-2013, 2022-2023)
Global Quality Supply Management: Biomanufacturers vs. CMOs
Global Quality Supply Management: U.S. vs. W. Europe
Addressing Supply Chain Security
5-8 Discussion: Industry Trends
Overall Capacity Constraints

CHAPTER 6: FUTURE CAPACITY EXPANSIONS

6-1 Planned Future Capacity Expansions
Planned Future Capacity Expansions (2009-2028)
Planned Future Capacity Expansions: Biomanufacturers vs. CMOs, by 2028
Planned Five-Year Capacity Expansion: U.S. vs. Western European
Biomanufacturers
Planned Future Capacity Expansions

CHAPTER 7: OUTSOURCING TRENDS IN BIOPHARMACEUTICAL

MANUFACTURING

Why Outsource?

Relating Outsourcing to Workforce Reduction

Strategic Manufacturing Planning

Future Projections

7-1 Current Outsourcing by Production System

Facilities Currently Outsourcing No Production (All Production “In-house”) (2006-2023)

7-2 Future Outsourcing

Biotherapeutic Developers’ Outsourcing, 5-Year (2028) Projections, by System

Biomanufacturers Outsourcing Some Production in 2028

7-3 Outsourced Activities in Biopharmaceutical Manufacturing

Comparison of Biomanufacturers’ Outsourcing (2010-2023)

Increased Outsourced Activities, 24-Month Projections

Outsourcing Activities Projected at ‘Significantly Higher Levels’ (2010-2023)

Average Percentage of Activities Outsourced Today, 2023

Comparison of Outsourcing Activities (2010-2023)

Change in Spending on Outsourcing Activities

7-4 CMOs’ Problems with Their Clients

7-5 Country Selections for International Outsourcing (Offshoring) of Biomanufacturing
Country Selections for International Outsourcing (Offshoring) of Biomanufacturing, Over Five Years (2016-2023)
U.S. vs. Western European Respondents' Outsourcing Destinations
7-6 Offshoring Trends
5-Year Projection for Biomanufacturing International Outsourcing/Offshoring
5-Year Projection for Biomanufacturing International Outsourcing/Offshoring (2011-2023)
5-Year Projection for Average Percentages of Biomanufacturing International Outsourcing/Offshoring (2011-2023)
Outsourcing to New Regions (2020 data)
7-7 Discussion of Outsourcing and Offshoring
Selecting a CMO

CHAPTER 8: DISPOSABLES AND SINGLE USE SYSTEMS IN BIOPHARMACEUTICAL MANUFACTURING

8-1 Use of Disposables and Single-Use Systems
Disposables Applications in Biopharmaceutical Manufacturing
Trends in Disposable Applications (2006-2023)
Average Annual Growth Rate for Disposables: Market Penetration/Usage
17-Year Average Growth in Disposable Applications, Percentage-Point Gains
Disposable Use by Stage of Production/Application
Use of Disposables: Biomanufacturers vs. CMOs
8-2 Leachables and Extractables
8-3 Reasons for Increasing Use of Disposables & Single-Use Systems
Single Most Critical Reason for Increasing the Use of Disposables (2018 data)
8-4 Factors That May Restrict Use of Disposables
Most Critical Reasons for Restricting Use of Disposables (2019 data)
Most Important Reasons for Not Increasing Use of Disposables (2008-2019)
Top Reasons for Not Increasing the Use of Disposables: U.S. vs. Western Europe (2019)
Cell-Culture Problems due to Single-Use Devices (2022)
Cell-Culture Problems due to Single-Use Devices (2022 vs. 2021)
Recycling of Disposables (2020)
8-5 Single-Use Adoption Issues
Single-Use Adoption Issues (2018 data)
Single-use Adoption Factors, U.S. vs. Western Europe (2018 data)
8-6 Single-Use Failure Issues

Single-use Failures

Average Weeks Between Failures of Single-use Devices

8-7 Need for Single-use Sensors, and Bioreactor Attributes

Single-Use Sensor Technologies (2012-2017, 2019 data)

8-8 Satisfaction with Single-Use Device Vendors

Single-Use Attribute Importance Analysis

Single-Use Suppliers' Delivery Problems (2013-2023)

8-9 Single-Use Operations and Trends

Percentage of Unit Operations that are Single-Use

Percentage of Single-Use Device Usage in Biomanufacturing

8-10 Discussion: Single-use Bioprocessing

Single-use Advantages

Growth in the Use of Single-use Systems

Downstream Single-use Systems Usage

CMOs' Use of Single-use Equipment

Modular: The Next Trend after Single-Use?

Single-use Equipment Sourcing, Quality Issues, and L&E Testing

CHAPTER 9: DOWNSTREAM PURIFICATION

9-1 Impact of Downstream Processing on Capacity

Downstream Processing on Capacity

Impact of Downstream Processing on Capacity, Biomanufacturers vs. CMOs

Impact of Downstream Processing on Capacity, U.S. vs. Western European
Biomanufacturers

9-2 Specific Purification Step Constraints

Changes in Impact on Capacity of Purification Steps (2008-2023)

9-3 Downstream Purification Issues

Protein A and Alternatives (2022 data)

Changes in Perception of Protein A and Alternatives (2009-2017, 2020-2022)

Protein A Downstream Purification Issues, U.S. vs. Western Europe

9-4 mAb Purification Capacity Estimates

Upstream Production Titer vs. Max Capacity

9-5 New Downstream Processing Technologies

New Downstream Processing Solutions (2010-2023)

New Downstream Processing Technologies: Biomanufacturers vs. CMOs

New Downstream Processing Technologies: U.S. vs. Western Europe

9-6 Improvements to Downstream Operations

Improving Downstream Operations (2019 data)

Comparison of New Downstream Technology Implementation: Biomanufacturers vs. CMOs (2019 data)

9-7 Discussion: Industry Trends

Upstream Expression Titer Trends and Impact on Downstream Operations

Downstream Processing Solutions

CHAPTER 10: HIRING, EMPLOYMENT GROWTH, AND TRAINING IN BIOPHARMACEUTICAL MANUFACTURING

Introduction

No Substitute for on-the-job Training

10-1 Hiring Trends

Trends in New Hires, by Area (2008-2023)

10-2 Hiring in 2028: Five-year Trends

10-3 Hiring Challenges Today

Hiring Difficulties (2010-2023)

U.S. and Western Europe Hiring Difficulties

10-4 Training in Biopharmaceutical Manufacturing

Skills or Hands-On Training Required in New Hires in GMP Bioprocessing

10-5 Discussion: Training Industry Trends

Options Developing for Bioprocessing Training

Continued Growth in Biopharmaceutical Manufacturing Jobs

CHAPTER 11: NEW METHODS: CONTINUOUS AND PROCESS INTENSIFICATION, CELL AND GENE THERAPIES

Introduction to Continuous Processing

11-1 Continuous Bioprocessing and Process Intensification

Perfusion vs. Batch Fed Bioprocessing (2021-2023)

11-2 Perfusion Operations and Continuous Bioprocessing Operational Issues

Perfusion Operation Issues (2010-2016, 2020 data)

Perfusion vs. Batch Fed Bioprocessing

Evaluating or Considering CBP technologies (Upstream) Over the Next 12 Months

Evaluating or Considering CBP technologies (Downstream) Over the Next 12 Months

11-3 Cell and Gene Therapy Platforms

Future Cell and Gene Therapy Platforms (2019 data)

Cell and Gene Therapy Manufacturing Advancements (2018 data)

Cell Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure

Cell Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure

(2019-2023)

Gene Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure

Gene Therapy Manufacturing Improvements, Systems, Platforms, and Infrastructure

(2019-2023)

Cell and Gene Therapy GMP and Commercial Manufacturing

Cell and Gene Therapy GMP and Commercial Manufacturing (2020-2023)

Cell and Gene Therapy Capacity Plans for In-House Bioprocessing Facilities

Cellular and Gene Therapies Commercial Manufacturing Scales (2021 data)

11-4 Discussion

Continuous Bioprocessing and Perfusion Trends

Implementation of Continuous Bioprocessing

Perfusion: Progress in Adoption

CHAPTER 12: SUPPLIERS TO BIOPHARMACEUTICAL MANUFACTURING AND LIFE SCIENCES

12-1 Demographics

Areas of Involvement

Location of Vendor Sales

Biopharmaceutical Adjacent Industries and Supplier Impact: Alternative Proteins .428

Respondents' Primary Job

12-2 Growth Rate of Sales by Suppliers

Average Industry Growth Rate, By Segment

Supplier Annual Sales, Distribution

12-3 Budget Issues and Problems Faced by Industry Suppliers

Budget Challenges in 2023

Vendor Average Pricing Changes

12-4 Problems Clients Have with Their Vendors

Quality of Business Relationships with Suppliers

Quality of Business Relationships with Clients

Quality Problems Traced to Vendors

12-5 Impacts of COVID-19 on Suppliers' Activities

Impact of COVID-19 Pandemic on Vendors, Percent Indicating an INCREASE in COVID-Related Factors (2021-2023)

Biopharma Vendor Business Trends

Biopharma Vendor Business Trends (2010-2023)

12-6 Vendors' Products and Services

New Technology Areas in Development by Vendors

2023 Other New Technology Areas in Development

2022 Other New Technology Areas in Development
Suppliers' R&D Spending/Budgets for New Products/Services
Average Annual Suppliers' R&D Spending/Budgets for New Products/Services
(2017-2023)
12-7 Sales Staff Training
Days of Training Provided by Suppliers (2021 data)
Areas where Training May Help Sales Staff Perform, Trends (2010-2023)
Clients' Demands on Vendors
12-8 Biopharma Vendors' Financial Outlook for 2023
12-9 CMO Pricing Changes for Biopharmaceutical Services
12-10 Discussion: Biopharma Suppliers
Vendor and Industry Growth
Bioprocessing Vendors Will See Continued Market Growth
Single-use Systems Continue to Drive Sales
Trends Favor Increased Vendor Sales
Vendors are Offering More Services, Going for Larger Sales
Biopharma Suppliers in Emerging Regions
Biopharma Supplier Growth

List Of Figures

LIST OF FIGURES

- Fig 0.1: Area of Primary Involvement in Biopharmaceutical Manufacturing (2010-2023)
- Fig 0.2: Respondents' Job Responsibilities (2011-2023)
- Fig 0.3: Facility Location, 2023
- Fig 0.4: Facility Location, by Region
- Fig 0.5: Biopharmaceutical Manufacturing Systems, (2007-2023) Trends
- Fig 0.6: Phase of Development of Surveyed Respondents (2006-2023)
- Fig 0.7: Phase of Development of Surveyed Respondents (U.S. vs. Western Europe)
- Fig 0.8: Distribution of Employees at Facility, and Organization
- Fig 0.9: Distribution of Total Batches Run at Facility in Past 12 Months, by Scale of Production
- Fig 0.10: Distribution of Largest SINGLE-USE Bioreactor Capacity, 2023
- Fig 0.11: Distribution of Largest STAINLESS Bioreactor Capacity, 2023
- Fig 1.1: Percentage of Total Market Revenue: Top 50 Biopharmaceutical Products
- Fig 2.1: Numbers of Recombinant and Non-Recombinant Biopharmaceuticals Approved by FDA Since 1981
- Fig 2.3: Current Disposal Method for Single-Use Assemblies at End User Facilities
- Fig 2.4: Preferred Method of Disposal of Single-Use Assemblies
- Fig 2.5: Selected Areas--Single Most Important Biomanufacturing Trend or Operational Area Industry Must Focus Efforts (China, US, W. Europe, and ROW)
- Fig 2.6: Average Cost per Gram for PRIMARY Recombinant Protein (by region, 2022 – 2023)
- Fig 2.7: Capacity Utilization, By System (China), 2023 vs. 2022
- Fig 2.8: Selected Areas: Percent Expecting "Some" Increase in Budgets for 2023 (Global)
- Fig 2.9: Selected Cost-Cutting Changes: Actions in "Past 12 Months" (Global), 2023
- Fig 2.10: Estimated Percentage of Facilities' Unit Operations that are "Single-Use" (Global), 2023
- Fig 2.11: Change in Spending on Outsourcing for R&D or Manufacturing, Next 12 Months (Global)
- Fig 2.12: End User (Biomanufacturer) Facility Changes in Ordering for Bioprocess Supplies and Consumables (Past 12 Mo)
- Fig 2.13: Changes in Orders in Past 2-6 Months (Suppliers' Perceptions in mid-2022)
- Fig 2.14: Expected Competition Among Suppliers to Reduce Prices and Expenditures
- Fig 2.15: Forecast for Competition (Suppliers' Perspective)
- Fig 2.16: Industry Comparative (Perceived) Average Lead Times End-users vs

Suppliers for Consumables and Services (Weeks)

Fig 3.1: SINGLE Most Important Biomanufacturing Trend or Operational Area Industry Must Focus Effort (2014-2023)

Fig 3.2: Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months, 2023

Fig 3.3: Novel Bioprocessing Systems/Innovations to Evaluate in Next 12 Months (Biomanufacturers vs. CMOs), 2023

Fig 3.4: Operational Changes Due to Recent Global Economics, 2023

Fig 3.5: Operational Changes Due to Recent Global Economics (2010 - 2012, 2022-2023)

Fig 3.6: Operational Changes Due to Recent Global Economics; Biomanufacturers vs. CMOs, 2023

Fig 3.7: Operational Changes Due to Recent Global Economics; U.S. vs. Western Europe, 2023

Fig 3.8: Biomanufacturers' Budget Shifts, 2023

Fig 3.9: Approximate Average Change in Biomanufacturers' Budgets, 2023

Fig 3.10: Average Biomanufacturers' Budget Changes (2009-2023)

Fig 3.11: New Bioprocessing Expenditures Focus Areas in the Past Year, 2023

Fig 3.12: Top NEW Bioprocessing Expenditure Focus Areas in Past Year (2020-2023)

Fig 3.13: New Product Development-Upstream Focus Areas, 2023

Fig 3.14: Upstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts (2010-2023)

Fig 3.15: Downstream New Product Development Areas Cited Where Suppliers Should Focus Development Efforts, 2023

Fig 3.16: New Product Development-Downstream Focus Areas (2010-2023)

Fig 3.17: New Product Development – General Focus Areas, Biomanufacturers & CMOs, 2023

Fig 3.18: New Product Development – General Focus Areas (2010-2023)

Fig 3.19: Top 10 New Product Development Areas of Interest: Biomanufacturers vs. CMOs, 2023

Fig 3.20: Top 10 New Product Development Areas of Interest: U.S. vs. Western Europe vs. ROW, 2023

Fig 3.21: Cost-Cutting Changes: Actions Undertaken During “Past 12 Months” Comparing (2011-2016, 2019-2023)

Fig 3.22: Cost-Cutting Changes, Outsourced Jobs, by Segment, and Geography (2011-2016, 2019-2023)

Fig 3.23: Factors That Will Have the Greatest Impact on Reducing Your Cost of Goods for Biotherapeutic Products, 2023

Fig 3.24: Distribution, Average Cost per Gram for PRIMARY Recombinant Protein, 2023

Fig 3.25: Distribution, Average Cost per Gram for PRIMARY Recombinant Protein

(2017-2023)

Fig 3.26: Biomanufacturing Assay “Areas” Urgently Requiring New, Improved Testing Methods (2011-2015, 2018-2019) (2019 data)

Fig 3.27: Largest Commercial-Scale Bioreactor Expected in the Next Two Years (2024) (2022 data)

Fig 3.28: Top Options for Bioreactor Platforms at Commercial Scale Manufacturing, 2023

Fig 3.29: Distribution of Largest Stainless Steel Bioreactor Capacity Next Two Years (2022 data)

Fig 3.30: Distribution of Largest SINGLE-USE Bioreactor Capacity Next Two Years (2022 data)

Fig 4.1: Capacity Utilization, By System, 2023

Fig 4.2: Capacity Utilization, By System (2006-2023)

Fig 4.3: Change in Capacity Utilization, CAGR (2006-2023)

Fig 4.4: Capacity Utilization, By System, Biomanufacturers vs. CMOs

Fig 4.5: Capacity Utilization, By System, U.S. vs. Western Europe

Fig 4.6: Current Production Capacity Distribution, Mammalian Cell Culture, 2023

Fig 4.7: Production Capacity Distribution, Mammalian Cell Culture (2010-2023)

Fig 4.8: Bioprocessing Concentration, Capacity Data, 2023

Fig 4.9: Current Production Capacity Distribution, Microbial Fermentation, 2023

Fig 4.10: Current Production Capacity Distribution, Cell Therapy, 2023

Fig 4.11: Production Capacity Distribution, Cell Therapy (2020-2023)

Fig 4.12: Current Production Capacity Distribution, Gene Therapy, 2023

Fig 4.13: Production Capacity Distribution, Gene Therapy (2020-2023)

Fig 4.14: Range of Titers for mAbs Obtained at Various Production Scales, Distribution

Fig 4.15: Average mAb Titer Trend (2008-2023)

Fig 5.1: Capacity Constraints, by Stage of Production, 2023

Fig 5.2: Capacity Constraints (2004-2023)

Fig 5.3: Capacity Constraints Trends (2004-2023)

Fig 5.4: Capacity Constraints, Biomanufacturers vs. CMOs, 2023

Fig 5.5: Capacity Constraints, U.S. vs. Western Europe, 2023

Fig 5.6: Expectations of Capacity Constraints by Stage of Production: Five-year Projections (by 2028)

Fig 5.7: Expectations of Capacity Constraints: Five-year Projections (2004-2023)

Fig 5.8: Expectations of Capacity Constraints: Five-year Projections (Trend Line) (2004-2023)

Fig 5.9: Five-year Projections for Capacity Constraints: Biomanufacturers vs. CMOs (2028)

Fig 5.10: Five-year Projections for Capacity Constraints: U.S. vs. Western Europe

(2028)

Fig 5.11: Factors Creating Future Capacity Constraints in Five Years, by 2028

Fig 5.12A: Factors Creating Future Capacity Constraints (2008-2023)

Fig 5.12B: Factors Creating Future Capacity Constraints (2008-2023)

Fig 5.13: Factors Creating Future Capacity Constraints: Biomanufacturers vs. CMOs, 2023

Fig 5.14: Factors Creating Future Capacity Constraints, U.S. vs. Western Europe Biomanufacturers, 2023

Fig 5.15: Key Areas to Address to Avoid Capacity Constraints, 2023

Fig 5.16A: Key Areas to Address to Avoid Capacity Constraints (2006-2023)

Fig 5.16B: Key areas to Address to Avoid Capacity Constraints (2006-2023)

Fig 5.17: Key Areas to Address to Avoid Capacity Constraints; Biomanufacturers Developers vs. CMOs, 2023

Fig 5.18: Key Areas to Address to Avoid Capacity Constraints; U.S. vs. Western Europe, 2023

Fig 5.19: Average Time (weeks) Between Batch Failures (2009-2023)

Fig 5.20: Batch Failure Frequency Distribution (2009-2023)

Fig 5.21: Average Rates of Failure, by Primary Cause, and Phase of Manufacture, 2023

Fig 5.22: Average Rates of Failure, by Primary Cause, and Phase of Manufacturing (“Commercial Manufacture”) (2009-2023)

Fig 5.23: Average Rates of Failure, by Primary Cause, and Phase of Manufacturing (“Clinical” Scale) (2009-2023)

Fig 5.24: Automation Technologies Implemented/to be Implemented in 2023

Fig 5.25: Automation Technologies to be Implemented; Comparing (2009 - 2013, 2022-2023)

Fig 5.26: Global Quality Supply Management, 2023

Fig 5.27: Global Quality Supply Management (2011-2013, 2022-2023)

Fig 5.28: Global Quality Supply Management, Biomanufacturers vs. CMOs, 2023

Fig 5.29: Global Quality Supply Management (U.S. vs. W. Europe), 2023

Fig 5.30: Addressing Supply Chain Security, 2023

Fig 6.1: Industry Average Planned Production Increase by 2028

Fig 6.2: Planned Future Capacity Expansion: Five-Year Estimates (2009–2028)

Fig 6.3: Planned Future Capacity Expansion: Five-year Estimates: Biomanufacturers vs. CMOs, by 2028

Fig 6.4: Planned Future Capacity Expansion: Five-Year Estimates: U.S. vs. Western Europe, by 2028

Fig 6.5: Percentage of Respondents Projecting Production Increases over 100% by 2028 (5-year Trend)

Fig 7.1: Current Percent Production Outsourced; by System, 2023

Fig 7.2: Biopharmaceutical Manufacturing Facilities Outsourcing NO Production (2006-2023)

Fig 7.3: Biotherapeutic Developers' Outsourcing, Five Year (2028) Projections, by System, 2023

Fig 7.4: Five Year Projections: % Biotherapeutic Developers Planning to Outsource at Least Some Production; Projections made 2007-2023

Fig 7.5: Biomanufacturers Outsourcing Some Activity Today, 2023

Fig 7.6A: Percent of Biomanufacturers Outsourcing at Least Some Activity Today (2010-2023)

Fig 7.6B: Percent of Biomanufacturers Outsourcing at Least Some Activity Today (2010-2023)

Fig 7.7: Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years, 2023

Fig 7.8A: Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years, Trends (2010-2023)

Fig 7.8B: Outsourcing Activities Projected to be Done at 'Significantly Higher Levels' in 2 Years, Trends (2010-2023)

Fig 7.9: Estimated Average Percentage of Activity Outsourced, by Facilities Today, 2023

Fig 7.10A: Estimated Average Percent of Activity Outsourced, by Facilities (2010-2023)

Fig 7.10B: Estimated Average Percent of Activity Outsourced, by Facilities (2010-2023)

Fig 7.11: Change in Spending on Outsourcing for R&D or Manufacturing, Next 12 months (2012-2023)

Fig 7.11A: Percent Indicating USA as Likely or Strong Likely Selection for INTERNATIONAL (non-US respondents) Outsourcing Over Next Five Years, 2009-2023 (targeting 2028)

Fig 7.12: Country Selections for International Outsourcing/Capacity Expansion Over Next Five Years, 2028

Fig 7.13A: Country Selections for "Possible" International Outsourcing/Capacity Expansion Over Next Five Years (2016-2023)

Fig 7.13B: Country Selections for "Possible" International Outsourcing/Capacity Expansion Over Next Five Years (2016-2023)

Fig 7.14A: U.S. Respondents Considering International Country as "Possible" Outsourcing Destination, over Next Five Years (2009-2023)

Fig 7.14B: U.S. Respondents Considering International Country as "Possible" Outsourcing Destination, over Next Five Years (2009-2023)

Fig 7.15: U.S. Respondents Considering Country as "Strong likelihood" or "Likelihood" as Outsourced Capacity Destination, Next Five Years (2028), 2023

Fig 7.16A: Western European Respondents Considering Country as "Possible"

Outsourcing Destination, Next Five Years, (2009-2023)

Fig 7.16B: Western European Respondents Considering Country as “Possible”

Outsourcing Destination, Next Five Years, (2009-2023)

Fig 7.17: Western European Respondents Considering Country as ‘Strong likelihood’ or ‘Likelihood’ as Outsourced Capacity Destination, over Next Five Years (2028), 2023

Fig 7.18: Percent of Biomanufacturing Operations Offshored (International Outsourcing) within Five Years (2028), 2023

Fig 7.19: Biomanufacturers Performing at Least “Some” International Outsourcing/Offshoring Over Next Five Years (2011-2023)

Fig 7.20: Estimated Average Percentage of Operations to be Done as International Outsourcing/Offshoring during Next Five Years (2011-2023)

Fig 8.1: Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture, 2023

Fig 8.2A: Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture (2006-2023)

Fig 8.2B: Usage of Disposables in Biopharmaceutical Manufacturing, Any Stage of R&D or Manufacture (2006-2023)

Fig 8.3: Average Annual Growth Rate, Disposables (2006-2023)

Fig 8.4: 17-Year Percentage-Point Increase in First Usage of Disposables (2006-2023)

Fig 8.5: Usage of Disposables in Biomanufacturing by Stage of Manufacture (R&D–Commercial), 2023

Fig 8.6: Usage of Disposables in Biopharmaceutical Manufacturing: Biomanufacturers vs. CMOs, 2023

Fig 8.7: Cell Culture Problems Due to Single-Use Devices (2022 vs. 2021)

Fig 8.8: Single-use Recycling; Respondents’ Desires for Disposal vs. Actual Disposal Process (2020 data)

Fig 8.9: Percent of Respondents Indicating Single-use Failures by Time and SUS Type, 2023

Fig 8.10: Average Weeks Before Failure of SUS Devices, 2023

Fig 8.11: Need for Improved Single-Use Sensors (2012-2017, 2019) (2019 data)

Fig 8.12: Single-Use Product Vendor Satisfaction Factors (2008-2023)

Fig 8.13: Importance of Single-Use Product Attributes vs. Level of Vendor Satisfaction, 2023

Fig 8.14: Percentage Point Gap between Importance of SUS Product Attributes and Level of Satisfaction (2013-2023)

Fig 8.15: Estimated Percentage of Facilities’ Unit Operations that are “Single-Use” (2014-2023)

Fig 8.16: Distribution of Responses, % Single-Use Devices in Biomanufacturing, 2023

Fig 9.1: Impact of Downstream Processing on Overall Capacity (2008-2023)

- Fig 9.2: Impact of Downstream Processing on Overall Capacity; Biotherapeutic Developers vs. CMOs
- Fig 9.3: Impact of Downstream Processing on Overall Capacity; U.S. vs. Western Europe
- Fig 9.4: Impact on Capacity of Depth, Chromatography and UF Purification Steps
- Fig 9.5: Impact on Capacity of Purification Steps: Experiencing at 'Significant' or 'Severe' Constraints (2008-2023)
- Fig 9.6: Impact on Capacity of Purification Steps, U.S. vs. Western Europe
- Fig 9.7: Issues Regarding Protein A Usage (2022 data)
- Fig 9.8: Issues Regarding Protein A Usage (2009-2017, 2020-2022)
- Fig 9.9: Issues Regarding Protein A Usage; U.S. vs. Western Europe (2022 data)
- Fig 9.10: mAb Operations: Upstream Production Titer (Distribution of Responses (2014-2016, 2018-2023)
- Fig 9.11: Bioreactor Output at which DOWNSTREAM Purification Train Becomes Bottlenecked (2014-2016, 2018-2023)
- Fig 9.12: New Downstream Processing Solution, 2023
- Fig 9.13A: New Downstream Processing Solutions Comparison (2010-2023)
- Fig 9.13B: New Downstream Processing Solutions Comparison (2010-2023)
- Fig 9.14: New Downstream Processing Solutions: Biomanufacturers vs. CMOs, 2023
- Fig 9.15: New Downstream Processing Solutions: U.S. vs. Western Europe, 2023
- Fig 9.16: Improving Downstream Operations, 2011-2019 (2019 data)
- Fig 10.1: New Hires in Biopharmaceutical Manufacturing, 2023
- Fig 10.2: Estimated Hiring, by Area (2008-2023)
- Fig 10.3: New Hires in Biopharmaceutical Manufacturing in Five Years (2028)
- Fig 10.4: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, 2023
- Fig 10.5A: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations (2010-2023)
- Fig 10.5B: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations (2010-2023)
- Fig 10.6: Areas Where Hiring Difficulties Exist in Biopharmaceutical Operations, U.S. vs. Western Europe, 2023
- Fig 10.7: Skills or Hands-On Training Required in NEW HIRES in GMP Bioprocessing
- Fig 11.1: Future of Continuous Bioprocessing and Process Intensification, 2023
- Fig 11.2: Future of Continuous Bioprocessing and Process Intensification (2021-2023)
- Fig 11.3: Perfusion Operations Issues (2010 – 2016, 2020, 2023)
- Fig 11.4: Concerns Over Perfusion Processes vs. Batch-fed Processes in Bioprocessing, 2023
- Fig 11.5: Faci

I would like to order

Product name: 2023 20th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

Product link: <https://marketpublishers.com/r/18B83BBCB7FEN.html>

Price: US\$ 3,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/18B83BBCB7FEN.html>